Skip to main content
Premium Trial:

Request an Annual Quote

Sanofi Partners with Adaptive Biotechnologies for Multiple Myeloma Trials

NEW YORK (GenomeWeb) – Adaptive Biotechnologies and Sanofi plan to collaborate to assess minimal residual disease in patients with multiple myeloma who have undergone treatment with Sanofi's investigational anti-CD38 monoclonal antibody therapy, Adaptive said today.

Sanofi is currently developing the drug, called isatuximab, for newly diagnosed, relapsed, and/or refractory multiple myeloma patients. Under the terms of the agreement, the parties will use Adaptive's immune repertoire sequencing assay ClonoSeq to assess minimal residual disease in patients who have been treated with isatuximab. Adaptive will be responsible for seeking regulatory clearance of ClonoSeq for multiple myeloma and will receive upfront and potential future milestone payments.

"MRD status is being incorporated as an important clinical endpoint to assess response to therapy in patients with multiple myeloma and other lymphoid malignancies," Charles Sang, Adaptive's senior vice president of diagnostics, said in a statement.

Chad Robins, Adaptive's CEO, added that the firm looks forward to applying its technology to "help determine the depth and duration of response to isatuximab in MM-treated patients."

Financial terms of the agreement were not disclosed.